AdAlta Ltd (ASX:1AD)'s Tim Oldham speaks to a Chinese patent the company has secured for its lead asset, AD-214 — a drug candidate designed to combat idiopathic pulmonary fibrosis. Oldham says China is now the second-largest (and fastest-growing) pharmaceutical market in the world after the US, representing 11% of the global prescription drug market. The company is also entering collaborative partnerships to develop its i-body platform, while AdAlta is anticipating data from clinical studies into AD-214 in the coming months.
AdAlta secures Chinese permit for AD-214 candidate
